Literature DB >> 16879860

The treatment of venous thromboembolism in special populations.

Matthew T Rondina1, Robert C Pendleton, Michelle Wheeler, George M Rodgers.   

Abstract

Anticoagulant therapy for the typical venous thromboembolism patient is straightforward with predictably favorable outcomes. However, for certain patients with venous thromboembolism, there remains uncertainty and controversy about optimal treatment. These controversial areas include venous thromboembolism patients with: heparin resistance, renal insufficiency, morbid obesity, cancer, antiphospholipid antibody syndrome, recurrent thrombosis despite appropriate anticoagulation, and patients with unprovoked VTE who may or may not benefit from thrombophilia testing. This review summarizes the current data for these special patient populations with venous thromboembolism and provides our recommendations for management.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879860     DOI: 10.1016/j.thromres.2006.05.015

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada.

Authors:  Peter Thomson; Cynthia Brocklebank; William Semchuk
Journal:  Can J Hosp Pharm       Date:  2009-09

2.  A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.

Authors:  Matthew T Rondina; Nathan Wanner; Robert C Pendleton; Larry W Kraiss; Russell Vinik; Guy A Zimmerman; Marta Heilbrun; John M Hoffman; Kathryn A Morton
Journal:  Thromb Res       Date:  2011-07-29       Impact factor: 3.944

3.  Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective.

Authors:  Amisha M Parikh; Frederick A Spencer; Darleen Lessard; Catherine Emery; Ana Baylin; Crystal Linkletter; Robert J Goldberg
Journal:  Am J Kidney Dis       Date:  2011-08-27       Impact factor: 8.860

4.  Evaluation of initial heparin infusion rates for a high-dose protocol.

Authors:  Adam Smith; Eileen M Stock; Nathan Fewel; Michael Rose; Carrie L Griffiths
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

5.  Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.

Authors:  Andrew Freeman; Tuesdy Horner; Robert C Pendleton; Matthew T Rondina
Journal:  Am J Hematol       Date:  2012-05-06       Impact factor: 10.047

6.  Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

Authors:  Ana G Fonseca; David P D'Cruz
Journal:  J Autoimmune Dis       Date:  2008-11-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.